Member Info for DavidGreece

It's "you're" #justsaying.

Class action is no joke. FDA approval of things they can't approve being challenged is no joke when it's the sole business here. Plenty of uptake? The accounts say otherwise.

With the current cash burn too it's unsustainable. Be careful. Strong sell. If they can't even abide by disclosure rules on advising shareholders of law suits, or major retailers refusing to stock it or the malpractices they've been fined for then there is every reason to have no confidence

Does the latest RNS disclose the legal dispute over approvals? The fines over their malpractices, their worrying debt? Does it talk about finances or is that only reflected in the accounts where it tell you significant fundraising will be needed? What happens if FDA revoke approvals? Who are they going to sell the GM stock too when major retailers like Costco etc have point black refused to stock it? What does it have to justify the current MCAP of £58m odd? This is a seriously risky stock with red flags.

That's exactly what I've posted, from the RNS and with links to my sources. I don't mislead, I research. Strong sell given my previous posts.

Facts, definition noun plural noun: facts a thing that is known or proved to be true. "the most commonly known fact about hedgehogs is that they have fleas" synonyms: reality, actuality, certainty, factuality, certitude; More information used as evidence or as part of a report or news article. "even the most inventive journalism peters out without facts, and in this case there were no facts" synonyms: detail, piece of information, particular, item, specific, element, point, factor, feature, characteristic, respect, ingredient, attribute, circumstance, consideration, aspect, facet; More used to refer to a particular situation under discussion. noun: the fact that "despite the fact that I'm so tired, sleep is elusive"

These guys should be suspended for failing to disclose the legal battles, fines etc etc to shareholders? This is extremely price sensitive for them and they are required to disclose via RNS as effectively it could finish them.

In February 2016, the Board approved a debt funding of US$10.0 million by the Company’s majority shareholder, Intrexon. The facility matures on 1 March 2017, bears an interest rate of 10% and is convertible into the common shares of the Company. More dilution. So $11m worth of stock at 23p to land on maturity and dilute shareholders. Then you have the last placing which was done at 15p. Current MCAP is far too high here. Strong sell

On 24 February 2016, AquaBounty announced that it had agreed to a convertible debt facility of US$10.0 million with Intrexon to fund the next stage of development. This debt facility, together with the US$1.3 million of cash on hand at the start of 2016, will provide the Company with su cient funds to advance its plans. Subject to the progress of these plans, it is LIKELY A LARGER FUNDRAISING will follow before the end of 2016. Then you look at the accounts and this is really concerning The accompanying nancial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced net losses and negative cash ows from operations since its inception and has cumulative losses attributable to common stockholders of US$90.8 million and a total stockholders’ de cit of US$0.1 million as of 31 December 2015. The Company has historically nanced its operations through issuances of equity and the proceeds of debt instruments and will continue to do so until such time that the Company is able to achieve positive cash ows from operations. In June 2015, the Company closed on a fundraising resulting in net proceeds of US$3.0 million. Ouch

Was this even disclosed to shareholders? http://www.cbc.ca/news/canada/prince-edward-island/lawsuit-u-s-fda-approval-aqua-bounty-salmon-1.3514002 http://www.naturalnews.com/053319_GM_salmon_AquaBounty_fines.html http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2016/04/the-long-swim-continues-as-groups-sue-fda-over-ge-salmon.html Could be game over potentially here. Bit worried this hasn't been disclosed to shareholders and they haven't been kept updated http://www.organicaglaw.com/2016/04/will-genetically-modified-salmon-be-served-a-setback-in-the-food-court-consumer-groups-seek-to-stall-release-of-gm-fish/ http://modernfarmer.com/2015/11/costco-wont-sell-gmo-salmon/

Given the shocking revelations posted below with links I'm surprised there isn't a rush for the exit and strong sell off here. Approval being challenged in court, shareholders have been informed. Malpractices evident and major retailers refusing to take GM stock. Significant losses and major funding required before end of 2016? If that approval gets revoked they're in trouble here.

Given the financial position, massive dilution ahead, claims of retailers shunning the product, class action to sue over approval and possibly revocation of FDA approvals here and the failure to disclose all these matters and various claims of breaking the laws. This is a STRONG SELL IMO. All the best those that take a position, I'd be extremely worried here.

http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2016/04/the-long-swim-continues-as-groups-sue-fda-over-ge-salmon.html Could be game over potentially here. Bit worried this hasn't been disclosed to shareholders and they haven't been kept updated.

http://www.organicaglaw.com/2016/04/will-genetically-modified-salmon-be-served-a-setback-in-the-food-court-consumer-groups-seek-to-stall-release-of-gm-fish/

http://modernfarmer.com/2015/11/costco-wont-sell-gmo-salmon/

Was this even disclosed to shareholders? http://www.cbc.ca/news/canada/prince-edward-island/lawsuit-u-s-fda-approval-aqua-bounty-salmon-1.3514002 http://www.naturalnews.com/053319_GM_salmon_AquaBounty_fines.html

These will be converted at 23p for $11m worth That's worrying dilution and before further placings they are suggesting that will be significant

In February 2016, the Board approved a debt funding of US$10.0 million by the Company’s majority shareholder, Intrexon. The facility matures on 1 March 2017, bears an interest rate of 10% and is convertible into the common shares of the Company. More dilution.

The Company is presently authorized to issue up to 240 million shares of stock, of which 40 million are authorized as preferred stock and 200 million as common stock. At 31 December 2015 the Company had zero shares (2014: zero) of preferred stock and 157,425,309 shares (2014: 144,537,265) of common stock, issued and outstanding. Last placing was at 15p.

The accompanying nancial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced net losses and negative cash ows from operations since its inception and has cumulative losses attributable to common stockholders of US$90.8 million and a total stockholders’ de cit of US$0.1 million as of 31 December 2015. The Company has historically nanced its operations through issuances of equity and the proceeds of debt instruments and will continue to do so until such time that the Company is able to achieve positive cash ows from operations. In June 2015, the Company closed on a fundraising resulting in net proceeds of US$3.0 million. Ouch